Compare GDV & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GDV | SLBT |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | 20 |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | N/A | N/A |
| Metric | GDV | SLBT |
|---|---|---|
| Price | $29.62 | $4.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 94.3K | ★ 236.9K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.75 | $3.23 |
| 52 Week High | $30.16 | $6.25 |
| Indicator | GDV | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 54.67 | 47.80 |
| Support Level | $28.58 | $3.63 |
| Resistance Level | $30.00 | $4.91 |
| Average True Range (ATR) | 0.27 | 0.74 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 49.74 | 33.44 |
Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, including Financial Services, Food and Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services, and others.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.